PLCB2 and breast neoplasm: The aggressive properties of CD133high cell are mitigated by PLC-β2 which, despite its general role in sustaining motility of breast tumor cells, down-modulates the expression of CD133 and thus may play a role in preventing metastatic progression of CD133 positive TNBC.